mProX™ Human TIGIT Stable Cell Line

Product Information

Target Family

Immune Checkpoint

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1;Human primary macrophages

Target Classification

Immune Checkpoint Cell Lines

Target Research Area

Cancer Research

Related Diseases

Colorectal Cancer; Chromophobe Renal Cell Carcinoma

Gene ID

Human:201633

UniProt ID

Human:Q495A1

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

TIGIT, or T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains, has been studied in various applications. In upper tract urothelial carcinoma (UTUC), TIGIT was found to be the second most represented immune checkpoint, with a median expression rate on tumor-infiltrating CD4+ T cells of 25% and 2.9% on circulating CD4+ T cells. It also showed expression on tumor-infiltrating CD8+ T cells. In head and neck squamous cell carcinoma (HNSCC), a predictive model involving TIGIT was constructed to predict tumor immune cell infiltration and drug sensitivity. The low-risk HNSCC group showed higher expression of TIGIT. In a phase I dose escalation study, the anti-TIGIT monoclonal antibody ociperlimab was used in combination with tislelizumab in patients with advanced solid tumors. The study evaluated the safety, pharmacokinetics, and preliminary antitumor activity of the combination therapy. In a study on cancer immunotherapy, a supramolecular bispecific cell engager (Supra-BiCE) targeting TIGIT was developed to augment natural killer (NK) and T cell-based immunotherapy. The Supra-BiCE interacted with NK/T cells via TIGIT and showed enhanced binding affinities to TIGIT within tumor regions. Finally, in pancreatic cancer, S100P was identified as a potential biomarker for an immunosuppressive microenvironment. S100P expression was negatively correlated with immune cell infiltration, particularly CD8+ T cells, and showed a correlation with TIGIT expression. These studies highlight the diverse applications of TIGIT in cancer research and immunotherapy.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human TIGIT Stable Cell Line (S01YF-1023-PY186). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Cameron Jones (Verified Customer)

How does TIGIT influence immune checkpoint blockade in cancer? Apr 09 2021

chat Patrick Liam (Creative Biolabs Scientific Support)

TIGIT plays a crucial role as a checkpoint inhibitor, interacting with the activating counter-receptor CD226. Its blockade, combined with PD-1 inhibition, is necessary for full restoration of CD226 signaling and optimal anti-tumor CD8+ T cell responses. Apr 09 2021

chat Alex Williams (Verified Customer)

What is the relationship between TIGIT and natural killer cell cytotoxicity? Aug 22 2021

chat Patrick Liam (Creative Biolabs Scientific Support)

TIGIT is expressed by all human NK cells and inhibits NK cytotoxicity directly through its ITIM, binding PVR and PVRL2 but not PVRL3, providing an "alternative self" mechanism for MHC class I inhibition. Aug 22 2021

Published Data

Fig.1 Functional defects are exhibited by CD8+ T cells from AML patients, and these defects can be ameliorated through TIGIT knockdown.

Significant reduction in TIGIT expression on CD8+ T cells was achieved through TIGIT knockdown. Representative flow data (left) and a plot of TIGIT MFI (right) on CD8+ T cells transfected with TIGIT siRNA as opposed to nonspecific (NS) siRNA were displayed. Furthermore, apoptosis was notably diminished as a result of TIGIT knockdown. A representative histogram (left) and plot (right) of Annexin V expression in 7AAD− CD8+ T cells were exhibited. P values were derived from the paired t test.

Ref: Kong, Yaxian, et al. "T-cell immunoglobulin and ITIM domain (TIGIT) associates with CD8+ T-cell exhaustion and poor clinical outcome in AML patients." Clinical Cancer Research 22.12 (2016): 3057-3066.

Pubmed: 26763253

DOI: 10.1158/1078-0432.CCR-15-2626

Research Highlights

Wang, Lang. et al. "A novel immune-related prognostic model with surgical status to predict tumor immune cell infiltration and drug sensitivity in head and neck squamous cell carcinoma." Biochemistry and biophysics reports, 2023.
In head and neck squamous cell carcinoma (HNSCC), Tumor-infiltrating immune cells (TICs) play a significant role in tumorigenesis and tumor development. A novel predictive model for HNSCC was developed using immune-related genes (IRGs) sourced from The Cancer Genome Atlas and the Immunology Database and Analysis Portal. Using multiple support vector machine recursive feature elimination and least absolute shrinkage and selection operator regression, a predictive model incorporating 13 IRGs with a high stratification value for overall survival (OS) was constructed. The relationship between risk score (RS) and clinical characteristics was also explored. The resulting nomogram demonstrated high concordance and good agreement for OS. Four TICs were identified to significantly impact OS, which corresponded to the abundance analysis of RS levels. The low-risk HNSCC group exhibited higher expression of PD-1, CTLA4, and TIGIT, while the high-risk group had higher expression of EGFR. Additionally, the high-risk HNSCC group showed high sensitivity to eight drugs.
Wang, Lang. et al. "A novel immune-related prognostic model with surgical status to predict tumor immune cell infiltration and drug sensitivity in head and neck squamous cell carcinoma." Biochemistry and biophysics reports, 2023.
Pubmed: 37868302 DOI: 10.1016/j.bbrep.2023.101557

Frentzas, Sophia. et al. "AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors." Journal for immunotherapy of cancer, 2023.
The monoclonal antibody Ociperlimab, which has been humanized, has a specific and strong binding ability to T-cell immunoreceptor TIGIT. Similarly, Tislelizumab, an anti-programmed cell death protein 1 mAb, also exhibits potent effects. The primary objective of this research, a phase I, first-in-human, dose escalation study, was to assess the safety, pharmacokinetics (PK), and preliminary antitumor activity of the combination treatment of Ociperlimab and Tislelizumab in patients with advanced solid tumors.
Frentzas, Sophia. et al. "AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors." Journal for immunotherapy of cancer, 2023.
Pubmed: 37857528 DOI: 10.1136/jitc-2022-005829